US researchers have recently reported that urine test is a better option for detecting prostate cancer than blood test or a rectal exam that are performed presently, alone.

Member of the team of the research, Dr. David Crawford of the University Of Colorado School Of Medicine said that Gen-Probe's Progensa PCA3 test diagnosed half the exact cases of prostate cancer in male, having abnormal PSA levels or digital rectal exams plus 20% "false positive" rate.

It is known that identifying a person with prostate cancer is one of the most difficult tasks a doctor has to perform.

Although, Digital rectal exams also help detect the enlargement in prostate, but this is a factor that comes with age as well as cancer.

On the other hand, blood test for prostate specific antigen PSA informs when the PSA level increases, but again the problem is that PSA levels elevate with normal enlargement of the prostate or because of some infection.

Another detection procedure includes Biopsies, but this is also risky as it is painful, and requires a healthy portion of prostate. This sometimes results in removal of part without any tumors.

It has been earlier revealed that about 1 million men in the United States were unnecessarily treated for prostate tumors and there prevailed a risk for every treatment that the patient would have died.

In Progensa test, genetic material named PCA3 is observed which in prostate cancer is over expressed, or overactive.